Identification

Name
Dyphylline
Accession Number
DB00651  (APRD00769)
Type
Small Molecule
Groups
Approved
Description

A theophylline derivative with broncho- and vasodilator properties. It is used in the treatment of asthma, cardiac dyspnea, and bronchitis. [PubChem]

Structure
Thumb
Synonyms
  • (+-)-7-(2,3-Dihydroxypropyl)theophylline
  • (+-)-Diprophylline
  • (+-)-Dyphylline
  • (±)-diprophylline
  • (±)-dyphylline
  • (1,2-Dihydroxy-3-propyl)thiophyllin
  • 1,3-Dimethyl-7-(2,3-dihydroxypropyl)xanthine
  • 7-(2,3-Dihydroxypropyl)-1,3-dimethylxanthine
  • 7-(2,3-Dihydroxypropyl)-3,7-dihydro-1,3-dimethyl-1H-purine-2,6-dione
  • 7-(2,3-Dihydroxypropyl)theophylline
  • 7-(beta,gamma-Dihydroxypropyl)theophylline
  • 7-(β,γ-dihydroxypropyl)theophylline
  • Dihydroxypropyl theopylin
  • Diprofilina
  • Diprophylline
  • Diprophyllinum
  • Dyphylline
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Protophylline Elixir 100mgElixir100 mgOralRougier Pharma Division Of Ratiopharm Inc1962-12-311999-09-27Canada
Protophylline Inj 500mg/2mlLiquid500 mgIntramuscular; IntravenousRougier Pharma Division Of Ratiopharm Inc1963-12-311999-09-27Canada
Protophylline Solution 100mgSolution100 mgOralRougier Pharma Division Of Ratiopharm Inc1965-12-311999-09-27Canada
Protophylline Sup 500mg AdultesSuppository500 mgRectalRougier Pharma Division Of Ratiopharm Inc1962-12-311999-09-27Canada
Protophylline Tab 200mgTablet200 mgOralRougier Pharma Division Of Ratiopharm Inc1962-12-311999-09-27Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
LufyllinTablet200 mg/1OralMeda Pharmaceuticals Ltd1976-08-312016-02-29Us
LufyllinTablet400 mg/1OralMeda Pharmaceuticals Ltd1976-08-312015-01-31Us
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Dilex-G 400Dyphylline (200 mg/1) + Guaifenesin (400 mg/1)TabletOralPoly Pharmaceuticals2006-09-082011-09-30Us
Dy GDyphylline (100 mg/5mL) + Guaifenesin (100 mg/5mL)LiquidOralCypress Pharmaceuticals, Inc.2001-10-312011-08-26Us
Dyphylline and GuaifenesinDyphylline (200 mg/1) + Guaifenesin (200 mg/1)TabletOralBreckenridge Pharmaceutical, Inc.2001-08-012012-02-29Us
Dyphylline GGDyphylline (200 mg/1) + Guaifenesin (200 mg/1)TabletOralPegasus Laboratories2006-12-182012-06-30Us
Dyphylline GgDyphylline (100 mg/15mL) + Guaifenesin (100 mg/15mL)ElixirOralSilarx Pharmaceuticals, Inc.1996-12-052011-06-02Us
Dyphylline GG ESDyphylline (200 mg/1) + Guaifenesin (300 mg/1)TabletOralBreckenridge Pharmaceutical, Inc.2008-02-012012-02-28Us
Jay-PhylDyphylline (100 mg/5mL) + Guaifenesin (50 mg/5mL)SyrupOralJaymac Pharmaceuticals Llc2006-05-022012-10-31Us
Lufyllin -GGDyphylline (100 mg/15mL) + Guaifenesin (100 mg/15mL)SolutionOralMeda Pharmaceuticals Ltd1968-06-012013-03-31Us
Theospect ImprovedDyphylline (200 mg/1) + Guaifenesin (200 mg/1)TabletOralPRN Pharmacal2000-01-132010-05-03Us
International/Other Brands
Corphyllin (Nippon Shinyaku) / Dilor (Savage)
Categories
UNII
263T0E9RR9
CAS number
479-18-5
Weight
Average: 254.2426
Monoisotopic: 254.101504956
Chemical Formula
C10H14N4O4
InChI Key
KSCFJBIXMNOVSH-UHFFFAOYSA-N
InChI
InChI=1S/C10H14N4O4/c1-12-8-7(9(17)13(2)10(12)18)14(5-11-8)3-6(16)4-15/h5-6,15-16H,3-4H2,1-2H3
IUPAC Name
7-(2,3-dihydroxypropyl)-1,3-dimethyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione
SMILES
CN1C2=C(N(CC(O)CO)C=N2)C(=O)N(C)C1=O

Pharmacology

Indication

For relief of acute bronchial asthma and for reversible bronchospasm associated with chronic bronchitis and emphysema.

Pharmacodynamics

Dyphylline, a xanthine derivative, is a bronchodilator used for relief of acute bronchial asthma and for reversible bronchospasm associated with chronic bronchitis and emphysema. Dyphylline is a xanthine derivative with pharmacologic actions similar to theophylline and other members of this class of drugs. Its primary action is that of bronchodilation, but it also exhibits peripheral vasodilatory and other smooth muscle relaxant activity to a lesser degree.

Mechanism of action

The bronchodilatory action of dyphylline, as with other xanthines, is thought to be mediated through competitive inhibition of phosphodiesterase with a resulting increase in cyclic AMP producing relaxation of bronchial smooth muscle as well as antagonism of adenosine receptors.

TargetActionsOrganism
AcAMP-specific 3',5'-cyclic phosphodiesterase 4B
inhibitor
Human
AcAMP-specific 3',5'-cyclic phosphodiesterase 4A
inhibitor
Human
AcAMP-specific 3',5'-cyclic phosphodiesterase 4C
inhibitor
Human
AcAMP-specific 3',5'-cyclic phosphodiesterase 4D
inhibitor
Human
AAdenosine receptor A1
antagonist
Human
AAdenosine receptor A2a
antagonist
Human
AHigh affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A
inhibitor
Human
AcAMP-specific 3',5'-cyclic phosphodiesterase 7B
inhibitor
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding

84%

Metabolism

Hepatic

Route of elimination

Dyphylline exerts its bronchodilatory effects directly and, unlike the­ophylline, is excreted unchanged by the kidneys without being metabolized by the liver. Approximately 88% of a single oral dose can be recovered from the urine unchanged.

Half life

2 hours (range 1.8 - 2.1 hours)

Clearance
Not Available
Toxicity

LD50=1954 mg/kg (orally in mice)

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINEThe serum concentration of Dyphylline can be decreased when it is combined with (1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINE.Experimental
1,10-PhenanthrolineThe serum concentration of Dyphylline can be decreased when it is combined with 1,10-Phenanthroline.Experimental
3,4-DichloroisocoumarinThe serum concentration of Dyphylline can be decreased when it is combined with 3,4-Dichloroisocoumarin.Experimental
4-(2-Aminoethyl)Benzenesulfonyl FluorideThe serum concentration of Dyphylline can be decreased when it is combined with 4-(2-Aminoethyl)Benzenesulfonyl Fluoride.Experimental
AbirateroneThe serum concentration of Dyphylline can be increased when it is combined with Abiraterone.Approved
AcetaminophenAcetaminophen may decrease the excretion rate of Dyphylline which could result in a higher serum level.Approved
Acetylsalicylic acidAcetylsalicylic acid may decrease the excretion rate of Dyphylline which could result in a higher serum level.Approved, Vet Approved
AllopurinolThe serum concentration of Dyphylline can be increased when it is combined with Allopurinol.Approved
AlogliptinThe serum concentration of Dyphylline can be decreased when it is combined with Alogliptin.Approved
AlprazolamAlprazolam may decrease the excretion rate of Dyphylline which could result in a higher serum level.Approved, Illicit, Investigational
AlprenololAlprenolol may decrease the bronchodilatory activities of Dyphylline.Approved, Withdrawn
AmilorideAmiloride may increase the excretion rate of Dyphylline which could result in a lower serum level and potentially a reduction in efficacy.Approved
AmlodipineAmlodipine may decrease the excretion rate of Dyphylline which could result in a higher serum level.Approved
AmobarbitalThe serum concentration of Dyphylline can be decreased when it is combined with Amobarbital.Approved, Illicit
AmoxicillinDyphylline may decrease the excretion rate of Amoxicillin which could result in a higher serum level.Approved, Vet Approved
AmphetamineAmphetamine may decrease the excretion rate of Dyphylline which could result in a higher serum level.Approved, Illicit, Investigational
AmpicillinAmpicillin may decrease the excretion rate of Dyphylline which could result in a higher serum level.Approved, Vet Approved
AmprenavirThe serum concentration of Dyphylline can be decreased when it is combined with Amprenavir.Approved, Investigational
Antithrombin III humanThe serum concentration of Dyphylline can be decreased when it is combined with Antithrombin III human.Approved
ApixabanThe serum concentration of Dyphylline can be decreased when it is combined with Apixaban.Approved
AprotininThe serum concentration of Dyphylline can be decreased when it is combined with Aprotinin.Approved, Investigational, Withdrawn
ArgatrobanThe serum concentration of Dyphylline can be decreased when it is combined with Argatroban.Approved, Investigational
AsunaprevirThe serum concentration of Dyphylline can be decreased when it is combined with Asunaprevir.Approved, Investigational, Withdrawn
AtazanavirThe serum concentration of Dyphylline can be decreased when it is combined with Atazanavir.Approved, Investigational
AtenololAtenolol may decrease the bronchodilatory activities of Dyphylline.Approved
AuranofinDyphylline may decrease the excretion rate of Auranofin which could result in a higher serum level.Approved, Investigational
BaclofenBaclofen may decrease the excretion rate of Dyphylline which could result in a higher serum level.Approved
BarbexacloneThe serum concentration of Dyphylline can be decreased when it is combined with Barbexaclone.Experimental
BarbitalThe serum concentration of Dyphylline can be decreased when it is combined with Barbital.Illicit
BatimastatThe serum concentration of Dyphylline can be decreased when it is combined with Batimastat.Experimental
BazedoxifeneThe serum concentration of Dyphylline can be increased when it is combined with Bazedoxifene.Approved, Investigational
BenazeprilThe serum concentration of Dyphylline can be decreased when it is combined with Benazepril.Approved, Investigational
BenzamidineThe serum concentration of Dyphylline can be decreased when it is combined with Benzamidine.Experimental
BisoprololBisoprolol may decrease the bronchodilatory activities of Dyphylline.Approved
BoceprevirThe serum concentration of Dyphylline can be decreased when it is combined with Boceprevir.Approved, Withdrawn
BopindololBopindolol may decrease the bronchodilatory activities of Dyphylline.Approved
BromazepamThe therapeutic efficacy of Bromazepam can be decreased when used in combination with Dyphylline.Approved, Illicit, Investigational
BudesonideDyphylline may decrease the excretion rate of Budesonide which could result in a higher serum level.Approved
BumetanideDyphylline may decrease the excretion rate of Bumetanide which could result in a higher serum level.Approved
BupranololBupranolol may decrease the bronchodilatory activities of Dyphylline.Approved
ButabarbitalButabarbital may decrease the excretion rate of Dyphylline which could result in a higher serum level.Approved, Illicit
CamazepamThe therapeutic efficacy of Camazepam can be decreased when used in combination with Dyphylline.Approved, Illicit
CamostatThe serum concentration of Dyphylline can be decreased when it is combined with Camostat.Experimental
CandoxatrilThe serum concentration of Dyphylline can be decreased when it is combined with Candoxatril.Experimental
CandoxatrilatThe serum concentration of Dyphylline can be decreased when it is combined with Candoxatrilat.Experimental
CarbimazoleThe serum concentration of Dyphylline can be increased when it is combined with Carbimazole.Approved, Investigational
CarteololCarteolol may decrease the bronchodilatory activities of Dyphylline.Approved
CeliprololCeliprolol may decrease the bronchodilatory activities of Dyphylline.Approved, Investigational
CevimelineCevimeline may decrease the excretion rate of Dyphylline which could result in a higher serum level.Approved
ChlordiazepoxideThe therapeutic efficacy of Chlordiazepoxide can be decreased when used in combination with Dyphylline.Approved, Illicit, Investigational
ChlorotrianiseneThe serum concentration of Dyphylline can be increased when it is combined with Chlorotrianisene.Investigational, Withdrawn
ChlorpromazineChlorpromazine may decrease the excretion rate of Dyphylline which could result in a higher serum level.Approved, Investigational, Vet Approved
ChlorzoxazoneChlorzoxazone may decrease the excretion rate of Dyphylline which could result in a higher serum level.Approved
ChymostatinThe serum concentration of Dyphylline can be decreased when it is combined with Chymostatin.Experimental
CilazaprilThe serum concentration of Dyphylline can be decreased when it is combined with Cilazapril.Approved
CinoxacinThe metabolism of Dyphylline can be decreased when combined with Cinoxacin.Approved, Investigational, Withdrawn
ClobazamThe therapeutic efficacy of Clobazam can be decreased when used in combination with Dyphylline.Approved, Illicit
ClonazepamDyphylline may decrease the excretion rate of Clonazepam which could result in a higher serum level.Approved, Illicit
CloranololCloranolol may decrease the bronchodilatory activities of Dyphylline.Experimental
ClorazepateClorazepate may decrease the excretion rate of Dyphylline which could result in a higher serum level.Approved, Illicit
Conjugated estrogensThe serum concentration of Dyphylline can be increased when it is combined with Conjugated estrogens.Approved
CyanocobalaminCyanocobalamin may decrease the excretion rate of Dyphylline which could result in a higher serum level.Approved, Nutraceutical
Dabigatran etexilateThe serum concentration of Dyphylline can be decreased when it is combined with Dabigatran etexilate.Approved
DaidzeinThe serum concentration of Dyphylline can be increased when it is combined with Daidzein.Experimental
DaptomycinDaptomycin may decrease the excretion rate of Dyphylline which could result in a higher serum level.Approved, Investigational
DarexabanThe serum concentration of Dyphylline can be decreased when it is combined with Darexaban.Investigational
DarunavirThe serum concentration of Dyphylline can be decreased when it is combined with Darunavir.Approved
DelanzomibThe serum concentration of Dyphylline can be decreased when it is combined with Delanzomib.Investigational
DelaprilThe serum concentration of Dyphylline can be decreased when it is combined with Delapril.Investigational
DelorazepamThe therapeutic efficacy of Delorazepam can be decreased when used in combination with Dyphylline.Approved, Illicit, Investigational
DiazepamDyphylline may decrease the excretion rate of Diazepam which could result in a higher serum level.Approved, Illicit, Investigational, Vet Approved
DiclofenacDiclofenac may decrease the excretion rate of Dyphylline which could result in a higher serum level.Approved, Vet Approved
DienestrolThe serum concentration of Dyphylline can be increased when it is combined with Dienestrol.Approved, Investigational
DiethylstilbestrolThe serum concentration of Dyphylline can be increased when it is combined with Diethylstilbestrol.Approved, Investigational
DiflunisalDiflunisal may decrease the excretion rate of Dyphylline which could result in a higher serum level.Approved, Investigational
DisulfiramThe serum concentration of Dyphylline can be increased when it is combined with Disulfiram.Approved
DosulepinThe serum concentration of Dyphylline can be increased when it is combined with Dosulepin.Approved
DoxefazepamThe therapeutic efficacy of Doxefazepam can be decreased when used in combination with Dyphylline.Experimental
DoxofyllineThe risk or severity of adverse effects can be increased when Dyphylline is combined with Doxofylline.Approved, Investigational
DoxycyclineDoxycycline may decrease the excretion rate of Dyphylline which could result in a higher serum level.Approved, Investigational, Vet Approved
EcabetThe serum concentration of Dyphylline can be decreased when it is combined with Ecabet.Approved, Investigational
EdoxabanThe serum concentration of Dyphylline can be decreased when it is combined with Edoxaban.Approved
ElafinThe serum concentration of Dyphylline can be decreased when it is combined with Elafin.Investigational
EnalaprilatThe serum concentration of Dyphylline can be decreased when it is combined with Enalaprilat.Approved
EnalkirenThe serum concentration of Dyphylline can be decreased when it is combined with Enalkiren.Experimental
EnoxacinThe metabolism of Dyphylline can be decreased when combined with Enoxacin.Approved, Investigational
EpimestrolThe serum concentration of Dyphylline can be increased when it is combined with Epimestrol.Experimental
EquolThe serum concentration of Dyphylline can be increased when it is combined with Equol.Investigational
EstazolamThe therapeutic efficacy of Estazolam can be decreased when used in combination with Dyphylline.Approved, Illicit
Estradiol acetateThe serum concentration of Dyphylline can be increased when it is combined with Estradiol acetate.Approved, Investigational, Vet Approved
Estradiol cypionateThe serum concentration of Dyphylline can be increased when it is combined with Estradiol cypionate.Approved, Investigational, Vet Approved
Estradiol valerateThe serum concentration of Dyphylline can be increased when it is combined with Estradiol valerate.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Dyphylline can be increased when it is combined with Estriol.Approved, Investigational, Vet Approved
Estrogens, esterifiedThe serum concentration of Dyphylline can be increased when it is combined with Estrogens, esterified.Approved
EstroneThe serum concentration of Dyphylline can be increased when it is combined with Estrone.Approved
EthambutolEthambutol may decrease the excretion rate of Dyphylline which could result in a higher serum level.Approved
EtizolamThe therapeutic efficacy of Etizolam can be decreased when used in combination with Dyphylline.Approved
FaldaprevirThe serum concentration of Dyphylline can be decreased when it is combined with Faldaprevir.Investigational
FebuxostatThe serum concentration of the active metabolites of Dyphylline can be increased when Dyphylline is used in combination with Febuxostat.Approved
FleroxacinThe serum concentration of Dyphylline can be increased when it is combined with Fleroxacin.Approved
FluconazoleFluconazole may decrease the excretion rate of Dyphylline which could result in a higher serum level.Approved, Investigational
FludiazepamThe therapeutic efficacy of Fludiazepam can be decreased when used in combination with Dyphylline.Approved, Illicit
FlumequineThe metabolism of Dyphylline can be decreased when combined with Flumequine.Withdrawn
FlunitrazepamThe therapeutic efficacy of Flunitrazepam can be decreased when used in combination with Dyphylline.Approved, Illicit
FlurazepamThe therapeutic efficacy of Flurazepam can be decreased when used in combination with Dyphylline.Approved, Illicit, Investigational
FlurbiprofenFlurbiprofen may decrease the excretion rate of Dyphylline which could result in a higher serum level.Approved, Investigational
Folic AcidFolic Acid may decrease the excretion rate of Dyphylline which could result in a higher serum level.Approved, Nutraceutical, Vet Approved
FormoterolThe risk or severity of adverse effects can be increased when Dyphylline is combined with Formoterol.Approved, Investigational
FosphenytoinThe serum concentration of Dyphylline can be decreased when it is combined with Fosphenytoin.Approved, Investigational
GabexateThe serum concentration of Dyphylline can be decreased when it is combined with Gabexate.Investigational
GadodiamideGadodiamide may decrease the excretion rate of Dyphylline which could result in a higher serum level.Approved, Investigational
GarenoxacinThe metabolism of Dyphylline can be decreased when combined with Garenoxacin.Investigational
GatifloxacinThe metabolism of Dyphylline can be decreased when combined with Gatifloxacin.Approved, Investigational
GeldanamycinThe serum concentration of Dyphylline can be decreased when it is combined with Geldanamycin.Experimental, Investigational
GemifloxacinThe metabolism of Dyphylline can be decreased when combined with Gemifloxacin.Approved, Investigational
GenisteinThe serum concentration of Dyphylline can be increased when it is combined with Genistein.Investigational
GentamicinGentamicin may decrease the excretion rate of Dyphylline which could result in a higher serum level.Approved, Vet Approved
GM6001The serum concentration of Dyphylline can be decreased when it is combined with GM6001.Experimental
GrepafloxacinThe metabolism of Dyphylline can be decreased when combined with Grepafloxacin.Approved, Investigational, Withdrawn
HaloperidolHaloperidol may decrease the excretion rate of Dyphylline which could result in a higher serum level.Approved
HexestrolThe serum concentration of Dyphylline can be increased when it is combined with Hexestrol.Withdrawn
HexobarbitalThe serum concentration of Dyphylline can be decreased when it is combined with Hexobarbital.Approved
HydralazineDyphylline may decrease the excretion rate of Hydralazine which could result in a higher serum level.Approved
HydroxocobalaminHydroxocobalamin may decrease the excretion rate of Dyphylline which could result in a higher serum level.Approved
IbuprofenIbuprofen may decrease the excretion rate of Dyphylline which could result in a higher serum level.Approved
IcosapentIcosapent may decrease the excretion rate of Dyphylline which could result in a higher serum level.Approved, Nutraceutical
IdraparinuxThe serum concentration of Dyphylline can be decreased when it is combined with Idraparinux.Investigational
ImidaprilThe serum concentration of Dyphylline can be decreased when it is combined with Imidapril.Investigational
ImipramineDyphylline may decrease the excretion rate of Imipramine which could result in a higher serum level.Approved
IndacaterolThe risk or severity of adverse effects can be increased when Dyphylline is combined with Indacaterol.Approved
IndomethacinIndomethacin may decrease the excretion rate of Dyphylline which could result in a higher serum level.Approved, Investigational
IopromideDyphylline may decrease the excretion rate of Iopromide which could result in a higher serum level.Approved
IoversolDyphylline may decrease the excretion rate of Ioversol which could result in a higher serum level.Approved
IsoflurophateThe serum concentration of Dyphylline can be decreased when it is combined with Isoflurophate.Approved, Investigational, Withdrawn
IsoniazidThe serum concentration of Dyphylline can be increased when it is combined with Isoniazid.Approved, Investigational
IxazomibThe serum concentration of Dyphylline can be decreased when it is combined with Ixazomib.Approved, Investigational
KetamineDyphylline may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Vet Approved
KetoprofenKetoprofen may decrease the excretion rate of Dyphylline which could result in a higher serum level.Approved, Vet Approved
KetorolacKetorolac may decrease the excretion rate of Dyphylline which could result in a higher serum level.Approved
LepirudinThe serum concentration of Dyphylline can be decreased when it is combined with Lepirudin.Approved
LetaxabanThe serum concentration of Dyphylline can be decreased when it is combined with Letaxaban.Investigational
LeuprolideLeuprolide may decrease the excretion rate of Dyphylline which could result in a higher serum level.Approved, Investigational
LevofloxacinThe metabolism of Dyphylline can be decreased when combined with Levofloxacin.Approved, Investigational
LevothyroxineThe metabolism of Dyphylline can be increased when combined with Levothyroxine.Approved
LinagliptinThe serum concentration of Dyphylline can be decreased when it is combined with Linagliptin.Approved
LiotrixThe metabolism of Dyphylline can be increased when combined with Liotrix.Approved
LisinoprilDyphylline may decrease the excretion rate of Lisinopril which could result in a higher serum level.Approved, Investigational
Lithium cationThe serum concentration of Lithium can be decreased when it is combined with Dyphylline.Experimental
LomefloxacinThe metabolism of Dyphylline can be decreased when combined with Lomefloxacin.Approved, Investigational
LopinavirThe serum concentration of Dyphylline can be decreased when it is combined with Lopinavir.Approved
LorazepamLorazepam may decrease the excretion rate of Dyphylline which could result in a higher serum level.Approved
LormetazepamThe therapeutic efficacy of Lormetazepam can be decreased when used in combination with Dyphylline.Approved
MannitolMannitol may decrease the excretion rate of Dyphylline which could result in a higher serum level.Approved, Investigational
MedazepamThe therapeutic efficacy of Medazepam can be decreased when used in combination with Dyphylline.Experimental
Medroxyprogesterone acetateMedroxyprogesterone acetate may decrease the excretion rate of Dyphylline which could result in a higher serum level.Approved, Investigational
MelagatranThe serum concentration of Dyphylline can be decreased when it is combined with Melagatran.Experimental
MepindololMepindolol may decrease the bronchodilatory activities of Dyphylline.Experimental
MestranolThe serum concentration of Dyphylline can be increased when it is combined with Mestranol.Approved
MetforminMetformin may decrease the excretion rate of Dyphylline which could result in a higher serum level.Approved
MethallenestrilThe serum concentration of Dyphylline can be increased when it is combined with Methallenestril.Experimental
MethohexitalThe serum concentration of Dyphylline can be decreased when it is combined with Methohexital.Approved
MethotrexateThe serum concentration of Dyphylline can be increased when it is combined with Methotrexate.Approved
MethylphenidateMethylphenidate may decrease the excretion rate of Dyphylline which could result in a higher serum level.Approved, Investigational
MethylphenobarbitalThe serum concentration of Dyphylline can be decreased when it is combined with Methylphenobarbital.Approved
MethylthiouracilThe serum concentration of Dyphylline can be increased when it is combined with Methylthiouracil.Experimental
MetolazoneMetolazone may decrease the excretion rate of Dyphylline which could result in a higher serum level.Approved
MexiletineThe metabolism of Dyphylline can be decreased when combined with Mexiletine.Approved, Investigational
MidazolamThe therapeutic efficacy of Midazolam can be decreased when used in combination with Dyphylline.Approved, Illicit
MidostaurinThe serum concentration of Dyphylline can be increased when it is combined with Midostaurin.Approved, Investigational
MilrinoneMilrinone may decrease the excretion rate of Dyphylline which could result in a higher serum level.Approved
MoexiprilThe serum concentration of Dyphylline can be decreased when it is combined with Moexipril.Approved
MoxestrolThe serum concentration of Dyphylline can be increased when it is combined with Moxestrol.Experimental
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of Dyphylline can be decreased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.Experimental
NadololNadolol may decrease the bronchodilatory activities of Dyphylline.Approved
NafamostatThe serum concentration of Dyphylline can be decreased when it is combined with Nafamostat.Approved, Investigational
Nalidixic AcidThe metabolism of Dyphylline can be decreased when combined with Nalidixic Acid.Approved, Investigational
NaproxenNaproxen may decrease the excretion rate of Dyphylline which could result in a higher serum level.Approved, Vet Approved
NebivololNebivolol may decrease the bronchodilatory activities of Dyphylline.Approved, Investigational
NemonoxacinThe metabolism of Dyphylline can be decreased when combined with Nemonoxacin.Investigational
NeomycinNeomycin may decrease the excretion rate of Dyphylline which could result in a higher serum level.Approved, Vet Approved
NitrazepamThe therapeutic efficacy of Nitrazepam can be decreased when used in combination with Dyphylline.Approved
NordazepamThe therapeutic efficacy of Nordazepam can be decreased when used in combination with Dyphylline.Approved
NorfloxacinThe metabolism of Dyphylline can be decreased when combined with Norfloxacin.Approved
OfloxacinThe metabolism of Dyphylline can be decreased when combined with Ofloxacin.Approved
OlodaterolThe risk or severity of adverse effects can be increased when Dyphylline is combined with Olodaterol.Approved
OmapatrilatThe serum concentration of Dyphylline can be decreased when it is combined with Omapatrilat.Investigational
OseltamivirOseltamivir may decrease the excretion rate of Dyphylline which could result in a higher serum level.Approved
OtamixabanThe serum concentration of Dyphylline can be decreased when it is combined with Otamixaban.Investigational
OxazepamThe therapeutic efficacy of Oxazepam can be decreased when used in combination with Dyphylline.Approved
Oxolinic acidThe metabolism of Dyphylline can be decreased when combined with Oxolinic acid.Experimental
OxprenololOxprenolol may decrease the bronchodilatory activities of Dyphylline.Approved
PancuroniumThe risk or severity of adverse effects can be increased when Dyphylline is combined with Pancuronium.Approved
PantoprazolePantoprazole may decrease the excretion rate of Dyphylline which could result in a higher serum level.Approved
ParoxetineDyphylline may decrease the excretion rate of Paroxetine which could result in a higher serum level.Approved, Investigational
PazufloxacinThe metabolism of Dyphylline can be decreased when combined with Pazufloxacin.Investigational
PefloxacinThe metabolism of Dyphylline can be decreased when combined with Pefloxacin.Approved
PenbutololPenbutolol may decrease the bronchodilatory activities of Dyphylline.Approved, Investigational
PentobarbitalThe serum concentration of Dyphylline can be decreased when it is combined with Pentobarbital.Approved, Investigational, Vet Approved
PentoxifyllineThe serum concentration of Dyphylline can be increased when it is combined with Pentoxifylline.Approved, Investigational
PerindoprilThe serum concentration of Dyphylline can be decreased when it is combined with Perindopril.Approved
PhosphoramidonThe serum concentration of Dyphylline can be decreased when it is combined with Phosphoramidon.Experimental
PindololDyphylline may decrease the excretion rate of Pindolol which could result in a higher serum level.Approved, Investigational
Pipemidic acidThe metabolism of Dyphylline can be decreased when combined with Pipemidic acid.Experimental
Piromidic acidThe metabolism of Dyphylline can be decreased when combined with Piromidic acid.Experimental
Polyestradiol phosphateThe serum concentration of Dyphylline can be increased when it is combined with Polyestradiol phosphate.Approved
Potassium ChlorideDyphylline may decrease the excretion rate of Potassium Chloride which could result in a higher serum level.Approved, Withdrawn
Potassium IodideThe serum concentration of Dyphylline can be increased when it is combined with Potassium Iodide.Approved
PrazepamThe therapeutic efficacy of Prazepam can be decreased when used in combination with Dyphylline.Approved, Illicit
PregabalinPregabalin may decrease the excretion rate of Dyphylline which could result in a higher serum level.Approved, Illicit, Investigational
PrimidoneThe serum concentration of Dyphylline can be decreased when it is combined with Primidone.Approved, Vet Approved
PrinomastatThe serum concentration of Dyphylline can be decreased when it is combined with Prinomastat.Investigational
ProbenecidThe serum concentration of Dyphylline can be increased when it is combined with Probenecid.Approved, Investigational
PromestrieneThe serum concentration of Dyphylline can be increased when it is combined with Promestriene.Investigational
PropranololPropranolol may decrease the excretion rate of Dyphylline which could result in a higher serum level.Approved, Investigational
PrulifloxacinThe metabolism of Dyphylline can be decreased when combined with Prulifloxacin.Investigational
PyridoxinePyridoxine may decrease the excretion rate of Dyphylline which could result in a higher serum level.Approved, Investigational, Nutraceutical, Vet Approved
QuazepamThe therapeutic efficacy of Quazepam can be decreased when used in combination with Dyphylline.Approved, Illicit
QuinestrolThe serum concentration of Dyphylline can be increased when it is combined with Quinestrol.Approved
QuinineThe serum concentration of Dyphylline can be increased when it is combined with Quinine.Approved
RacecadotrilThe serum concentration of Dyphylline can be decreased when it is combined with Racecadotril.Investigational
RemikirenThe serum concentration of Dyphylline can be decreased when it is combined with Remikiren.Approved
ReserpineReserpine may decrease the excretion rate of Dyphylline which could result in a higher serum level.Approved, Investigational
RiociguatDyphylline may increase the hypotensive activities of Riociguat.Approved
RitonavirThe serum concentration of Dyphylline can be decreased when it is combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Dyphylline can be decreased when it is combined with Rivaroxaban.Approved
RosoxacinThe metabolism of Dyphylline can be decreased when combined with Rosoxacin.Approved, Investigational
RufloxacinThe metabolism of Dyphylline can be decreased when combined with Rufloxacin.Experimental
S-3304The serum concentration of Dyphylline can be decreased when it is combined with S-3304.Investigational
SalbutamolDyphylline may decrease the excretion rate of Salbutamol which could result in a higher serum level.Approved, Vet Approved
Salmon CalcitoninSalmon Calcitonin may decrease the excretion rate of Dyphylline which could result in a higher serum level.Approved, Investigational
SaquinavirThe serum concentration of Dyphylline can be decreased when it is combined with Saquinavir.Approved, Investigational
SecobarbitalThe serum concentration of Dyphylline can be decreased when it is combined with Secobarbital.Approved, Vet Approved
SecoisolariciresinolThe serum concentration of Dyphylline can be increased when it is combined with Secoisolariciresinol.Investigational
SimeprevirThe serum concentration of Dyphylline can be decreased when it is combined with Simeprevir.Approved
SitafloxacinThe metabolism of Dyphylline can be decreased when combined with Sitafloxacin.Experimental, Investigational
SivelestatThe serum concentration of Dyphylline can be decreased when it is combined with Sivelestat.Investigational
Sodium aurothiomalateDyphylline may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.Approved, Investigational
SotalolSotalol may decrease the bronchodilatory activities of Dyphylline.Approved
SparfloxacinThe metabolism of Dyphylline can be decreased when combined with Sparfloxacin.Approved, Investigational
SpiraprilThe serum concentration of Dyphylline can be decreased when it is combined with Spirapril.Approved
SpironolactoneSpironolactone may increase the excretion rate of Dyphylline which could result in a lower serum level and potentially a reduction in efficacy.Approved
SucralfateSucralfate may decrease the excretion rate of Dyphylline which could result in a higher serum level.Approved
Synthetic Conjugated Estrogens, AThe serum concentration of Dyphylline can be increased when it is combined with Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Dyphylline can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
Technetium Tc-99m ciprofloxacinThe serum concentration of Dyphylline can be increased when it is combined with Technetium Tc-99m ciprofloxacin.Investigational
TelaprevirThe serum concentration of Dyphylline can be decreased when it is combined with Telaprevir.Approved, Withdrawn
TemafloxacinThe metabolism of Dyphylline can be decreased when combined with Temafloxacin.Withdrawn
TemazepamTemazepam may decrease the excretion rate of Dyphylline which could result in a higher serum level.Approved, Investigational
TemocaprilThe serum concentration of Dyphylline can be decreased when it is combined with Temocapril.Experimental, Investigational
TerbutalineDyphylline may decrease the excretion rate of Terbutaline which could result in a higher serum level.Approved
TertatololTertatolol may decrease the bronchodilatory activities of Dyphylline.Experimental
Testosterone cypionateDyphylline may decrease the excretion rate of Testosterone cypionate which could result in a higher serum level.Approved
Testosterone enanthateDyphylline may decrease the excretion rate of Testosterone enanthate which could result in a higher serum level.Approved
ThiabendazoleThe metabolism of Dyphylline can be decreased when combined with Thiabendazole.Approved, Vet Approved
ThiamylalThe serum concentration of Dyphylline can be decreased when it is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe serum concentration of Dyphylline can be decreased when it is combined with Thiopental.Approved, Vet Approved
ThiorphanThe serum concentration of Dyphylline can be decreased when it is combined with Thiorphan.Experimental
Thyroid, porcineThe metabolism of Dyphylline can be increased when combined with Thyroid, porcine.Approved
TiboloneThe serum concentration of Dyphylline can be increased when it is combined with Tibolone.Approved, Investigational
TiclopidineTiclopidine may decrease the excretion rate of Dyphylline which could result in a higher serum level.Approved
TimololTimolol may decrease the excretion rate of Dyphylline which could result in a higher serum level.Approved
TipranavirThe serum concentration of Dyphylline can be decreased when it is combined with Tipranavir.Approved, Investigational
TrandolaprilThe serum concentration of Dyphylline can be decreased when it is combined with Trandolapril.Approved
TriazolamThe therapeutic efficacy of Triazolam can be decreased when used in combination with Dyphylline.Approved, Investigational
TrimebutineDyphylline may decrease the excretion rate of Trimebutine which could result in a higher serum level.Approved
TrimethoprimTrimethoprim may decrease the excretion rate of Dyphylline which could result in a higher serum level.Approved, Vet Approved
TrovafloxacinThe metabolism of Dyphylline can be decreased when combined with Trovafloxacin.Approved, Investigational, Withdrawn
UbenimexThe serum concentration of Dyphylline can be decreased when it is combined with Ubenimex.Experimental, Investigational
UlinastatinThe serum concentration of Dyphylline can be decreased when it is combined with Ulinastatin.Investigational
VerapamilDyphylline may decrease the excretion rate of Verapamil which could result in a higher serum level.Approved
VildagliptinThe serum concentration of Dyphylline can be decreased when it is combined with Vildagliptin.Approved, Investigational
WarfarinDyphylline may decrease the excretion rate of Warfarin which could result in a higher serum level.Approved
XimelagatranThe serum concentration of Dyphylline can be decreased when it is combined with Ximelagatran.Approved, Investigational, Withdrawn
Z-Val-Ala-Asp fluoromethyl ketoneThe serum concentration of Dyphylline can be decreased when it is combined with Z-Val-Ala-Asp fluoromethyl ketone.Experimental
ZafirlukastThe serum concentration of Zafirlukast can be decreased when it is combined with Dyphylline.Approved, Investigational
ZeranolThe serum concentration of Dyphylline can be increased when it is combined with Zeranol.Vet Approved
ZofenoprilThe serum concentration of Dyphylline can be decreased when it is combined with Zofenopril.Experimental
Food Interactions
Not Available

References

Synthesis Reference

Jones, J.W. and Maney, P.V.; U.S. Patent 2,575,344; November 20,1951; assigned to the State of Iowa.

General References
Not Available
External Links
Human Metabolome Database
HMDB0014789
KEGG Drug
D00691
KEGG Compound
C07819
PubChem Compound
3182
PubChem Substance
46504443
ChemSpider
3070
BindingDB
82016
ChEBI
4728
ChEMBL
CHEMBL1752
Therapeutic Targets Database
DAP000596
PharmGKB
PA164748027
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Dyphylline
ATC Codes
R03DA51 — Diprophylline, combinationsR03DA01 — DiprophyllineR03DB01 — Diprophylline and adrenergics
MSDS
Download (65.7 KB)

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
  • Teva pharmaceuticals usa inc
  • Savage laboratories inc div altana inc
  • Meda pharmaceuticals inc
Packagers
  • Breckenridge Pharmaceuticals
  • Great Southern Laboratories
  • Lunsco Inc.
  • Meda AB
  • Novartis AG
  • Savage Labs
Dosage forms
FormRouteStrength
TabletOral
LiquidOral
ElixirOral
SyrupOral
TabletOral200 mg/1
TabletOral400 mg/1
SolutionOral
ElixirOral100 mg
LiquidIntramuscular; Intravenous500 mg
SolutionOral100 mg
SuppositoryRectal500 mg
TabletOral200 mg
Prices
Unit descriptionCostUnit
Afinitor 10 mg tablet247.58USD tablet
Afinitor 5 mg tablet234.75USD tablet
Lufyllin-400 tablet4.62USD tablet
Lufyllin 200 mg tablet3.15USD tablet
Dyphylline gg es tablet0.78USD tablet
Dyphylline gg tablet0.69USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)155-157Jones, J.W. and Maney, P.V.; U.S. Patent 2,575,344; November 20,1951; assigned to the State of Iowa.
water solubility3.33E+005 mg/L (at 25 °C)MERCK INDEX (1996)
logP-1.9Not Available
logS-0.17ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility14.3 mg/mLALOGPS
logP-0.98ALOGPS
logP-1.9ChemAxon
logS-1.2ALOGPS
pKa (Strongest Acidic)13.91ChemAxon
pKa (Strongest Basic)-0.97ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area98.9 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity62.09 m3·mol-1ChemAxon
Polarizability24.65 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.964
Blood Brain Barrier-0.6357
Caco-2 permeable-0.7332
P-glycoprotein substrateSubstrate0.5999
P-glycoprotein inhibitor INon-inhibitor0.9775
P-glycoprotein inhibitor IINon-inhibitor0.9792
Renal organic cation transporterNon-inhibitor0.9289
CYP450 2C9 substrateNon-substrate0.8343
CYP450 2D6 substrateNon-substrate0.8429
CYP450 3A4 substrateNon-substrate0.5446
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.946
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.978
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9758
Ames testNon AMES toxic0.799
CarcinogenicityNon-carcinogens0.8576
BiodegradationNot ready biodegradable0.6129
Rat acute toxicity1.8401 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9489
hERG inhibition (predictor II)Non-inhibitor0.8734
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-001i-9000000000-d159f2e06ae5688fe714
GC-MS Spectrum - EI-BGC-MSsplash10-001i-9000000000-d159f2e06ae5688fe714
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0a4i-0090000000-333eda23b5db828349a1
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0a4i-0390000000-b965183e8f0f1617c518
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-001i-0910000000-65b3ffefd28585f62d32
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0089-3900000000-e0a54464bc16e628c820
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-05gj-9700000000-b192c58457f7957424f1
LC-MS/MS Spectrum - LC-ESI-IT , positiveLC-MS/MSsplash10-001i-0920000000-973a36ebf151db89ccdc
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a59-2970000000-4ad8ef9bfa86cda3d221
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0089-2900000000-1b3e2d3408802f411886

Taxonomy

Description
This compound belongs to the class of organic compounds known as xanthines. These are purine derivatives with a ketone group conjugated at carbons 2 and 6 of the purine moiety.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Imidazopyrimidines
Sub Class
Purines and purine derivatives
Direct Parent
Xanthines
Alternative Parents
6-oxopurines / Alkaloids and derivatives / Pyrimidones / N-substituted imidazoles / Vinylogous amides / Heteroaromatic compounds / Secondary alcohols / Lactams / 1,2-diols / Ureas
show 6 more
Substituents
Xanthine / 6-oxopurine / Purinone / Alkaloid or derivatives / Pyrimidone / N-substituted imidazole / Pyrimidine / Azole / Imidazole / Heteroaromatic compound
show 16 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
oxopurine, propane-1,2-diols (CHEBI:4728)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Metal ion binding
Specific Function
Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes. May be involved in mediating central nervous system effects of therapeutic agents ranging f...
Gene Name
PDE4B
Uniprot ID
Q07343
Uniprot Name
cAMP-specific 3',5'-cyclic phosphodiesterase 4B
Molecular Weight
83342.695 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Iancu L, Shneur A, Cohen H: Trials with xanthine derivatives in systemic treatment of psoriasis. Dermatologica. 1979;159(1):55-61. [PubMed:225216]
  4. Hariton C: Ocular hypotension induced by topical dopaminergic drugs and phosphodiesterase inhibitors. Eur J Pharmacol. 1994 Jun 2;258(1-2):85-94. [PubMed:7925603]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Metal ion binding
Specific Function
Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes.
Gene Name
PDE4A
Uniprot ID
P27815
Uniprot Name
cAMP-specific 3',5'-cyclic phosphodiesterase 4A
Molecular Weight
98142.155 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  4. Iancu L, Shneur A, Cohen H: Trials with xanthine derivatives in systemic treatment of psoriasis. Dermatologica. 1979;159(1):55-61. [PubMed:225216]
  5. Hariton C: Ocular hypotension induced by topical dopaminergic drugs and phosphodiesterase inhibitors. Eur J Pharmacol. 1994 Jun 2;258(1-2):85-94. [PubMed:7925603]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Metal ion binding
Specific Function
Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes.
Gene Name
PDE4C
Uniprot ID
Q08493
Uniprot Name
cAMP-specific 3',5'-cyclic phosphodiesterase 4C
Molecular Weight
79900.795 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Iancu L, Shneur A, Cohen H: Trials with xanthine derivatives in systemic treatment of psoriasis. Dermatologica. 1979;159(1):55-61. [PubMed:225216]
  4. Hariton C: Ocular hypotension induced by topical dopaminergic drugs and phosphodiesterase inhibitors. Eur J Pharmacol. 1994 Jun 2;258(1-2):85-94. [PubMed:7925603]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Ubiquitin protein ligase binding
Specific Function
Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes.
Gene Name
PDE4D
Uniprot ID
Q08499
Uniprot Name
cAMP-specific 3',5'-cyclic phosphodiesterase 4D
Molecular Weight
91114.1 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Hariton C: Ocular hypotension induced by topical dopaminergic drugs and phosphodiesterase inhibitors. Eur J Pharmacol. 1994 Jun 2;258(1-2):85-94. [PubMed:7925603]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Purine nucleoside binding
Specific Function
Receptor for adenosine. The activity of this receptor is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
ADORA1
Uniprot ID
P30542
Uniprot Name
Adenosine receptor A1
Molecular Weight
36511.325 Da
References
  1. Schwabe U, Ukena D, Lohse MJ: Xanthine derivatives as antagonists at A1 and A2 adenosine receptors. Naunyn Schmiedebergs Arch Pharmacol. 1985 Sep;330(3):212-21. [PubMed:2997628]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Identical protein binding
Specific Function
Receptor for adenosine. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase.
Gene Name
ADORA2A
Uniprot ID
P29274
Uniprot Name
Adenosine receptor A2a
Molecular Weight
44706.925 Da
References
  1. Schwabe U, Ukena D, Lohse MJ: Xanthine derivatives as antagonists at A1 and A2 adenosine receptors. Naunyn Schmiedebergs Arch Pharmacol. 1985 Sep;330(3):212-21. [PubMed:2997628]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Metal ion binding
Specific Function
Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes. May have a role in muscle signal transduction.
Gene Name
PDE7A
Uniprot ID
Q13946
Uniprot Name
High affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A
Molecular Weight
55504.475 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Metal ion binding
Specific Function
Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes. May be involved in the control of cAMP-mediated neural activity and cAMP metabolism in the ...
Gene Name
PDE7B
Uniprot ID
Q9NP56
Uniprot Name
cAMP-specific 3',5'-cyclic phosphodiesterase 7B
Molecular Weight
51834.855 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]

Drug created on June 13, 2005 07:24 / Updated on August 02, 2018 04:24